

NYRx Notice to Providers: Dexcom G6 Continuous Glucose Monitor (CGM) Systems

February 24, 2026

What Pharmacy Providers and Prescribers Need to Know

NYRx, the Medicaid Pharmacy Program, claim history indicates you have prescribed or submitted claims for Dexcom G6 CGM products for a New York State Medicaid member within the past three months.

Effective **July 1, 2026**, the manufacturer of Dexcom G6 will discontinue this product line. Patients must receive new prescriptions for either the Dexcom G7 or Dexcom G7 15-day CGM system. Previously approved prior authorizations (PA) of the discontinued Dexcom G6 Sensors may be impacted and require a new PA.

What Prescribers Need to Do

Prescribers should update their patients' prescriptions to the Dexcom G7 or Dexcom G7 15-Day CGM product or switch their patients to an alternate product to prevent a disruption in care. For a complete list of Continuous Glucose Monitors covered by NYRx, see the [NYRx Preferred Diabetic Supply Program Resource](#).

For more information regarding the discontinuation of Dexcom G6, please visit [How much longer will Dexcom G6 be available? | Dexcom](#).

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Helpful Hints for Pharmacies: Diabetic Testing Supplies](#)
- [NYRx Preferred Diabetic Supply Program Resource](#)
- [NYRx Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.